Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Elective pelvic nodal radiotherapy: is the jury still out?

Nature Reviews Urology volume 13, pages 10–11 (2016)Cite this article

Subjects

Elective pelvic nodal irradiation (EPNI) remains a controversial area in prostate cancer management. Two articles published in the International Journal of Radiation, Oncology, Biology and Physics present additional data regarding the benefits of EPNI for patients with high-risk prostate cancer, suggesting that EPNI confers no benefit in overall survival or biochemical-progression-free survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Amini, A. et al. Survival outcomes of whole-pelvic versus prostate-only radiotherapy for high risk prostate cancer patients using the National Cancer Data Base. Int. J. Radiat. Oncol. Biol. Phys. http://dx.doi.org/10.1016/j.ijrobp.2015.09.006.

  2. Blanchard, P. et al. Outcome according to elective pelvic radiotherapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. http://dx.doi.org/10.1016/j.ijrobp.2015.09.020.

  3. Morikawa, L. K. & Roach, M. 3rd. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int. J. Radiat. Oncol. Biol. Phys. 80, 6–16 (2011).

    Article  Google Scholar 

  4. Lawton, C. A. et al. An update of the Phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 69, 646–655 (2007).

    Article  Google Scholar 

  5. NRG Oncology. Androgen deprivation therapy and radiotherapy in treating patients with prostate cancer. Cancer.gov [online].

  6. US National Library of Science. A Phase III Trial of cabazetaxel and pelvic radiotherapy for localized prostate cancer with high risk features for relapse (PEACE2). ClinicalTrials.gov [online].

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Professor of Radiation Oncology, University of British Columbia, BCCA Centre for the Southern Interior, 399 Royal Avenue, Kelowna, BC V1Y 5L3, Canada.,

    Juanita Crook

Authors
  1. Juanita Crook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juanita Crook.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crook, J. Elective pelvic nodal radiotherapy: is the jury still out?. Nat Rev Urol 13, 10–11 (2016). https://doi.org/10.1038/nrurol.2015.283

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2015.283

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing